RDHL
HEALTHCARERedhill Biopharma Ltd
$1.02+0.00 (+0.00%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RDHL Today?
No stock-specific AI insight has been generated for RDHL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.71$3.31
$1.02
Fundamentals
Market Cap$5M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-17.1%
Profit Margin-1.5%
Debt / Equity—
Trading
Volume23K
Avg Volume (10D)—
Shares Outstanding5.2M
RDHL News
20 articles- RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's DiseaseYahoo Finance·Apr 30, 2026
- RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational HighlightsYahoo Finance·Apr 27, 2026
- RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026Yahoo Finance·Apr 22, 2026
- CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®Yahoo Finance·Feb 25, 2026
- Joint U.S. Commercialization of RedHill's Talicia® CommencesYahoo Finance·Feb 25, 2026
- RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side EffectsYahoo Finance·Jan 5, 2026
- RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant CellsYahoo Finance·Dec 15, 2025
- RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity RequirementYahoo Finance·Dec 1, 2025
- RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for EnforcementYahoo Finance·Nov 4, 2025
- RedHill Biopharma Receives Nasdaq Staff Determination NotificationYahoo Finance·Oct 22, 2025
- CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIOYahoo Finance·Oct 20, 2025
- RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership DealYahoo Finance·Oct 20, 2025
- RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®Yahoo Finance·Oct 6, 2025
- RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against KukboYahoo Finance·Sep 29, 2025
- RedHill Biopharma Announces First Half 2025 Financial Results and Operational HighlightsYahoo Finance·Sep 5, 2025
- RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment WinYahoo Finance·Aug 20, 2025
- RedHill Received Talicia® Licensing Payments Totaling $1.1 MillionYahoo Finance·Aug 18, 2025
- RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's DiseaseYahoo Finance·Jul 21, 2025
- Sector Update: Health Care Stocks Rise in Late Afternoon TradingYahoo Finance·Jul 1, 2025
- RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate CancerYahoo Finance·Jul 1, 2025
All 20 articles loaded
Price Data
Open$1.02
Previous Close$1.02
Day High$1.05
Day Low$1.01
52 Week High$3.31
52 Week Low$0.71
52-Week Range
$0.71$3.31
$1.02
Fundamentals
Market Cap$5M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-17.1%
Profit Margin-1.5%
Debt / Equity—
Trading
Volume23K
Avg Volume (10D)—
Shares Outstanding5.2M
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company is headquartered in Tel Aviv, Israel.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—